Vera Therapeutics, Inc.

NasdaqGM:VERA Stock Report

Market Cap: US$2.9b

Vera Therapeutics Valuation

Is VERA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VERA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VERA ($47.03) is trading below our estimate of fair value ($417.57)

Significantly Below Fair Value: VERA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VERA?

Key metric: As VERA is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for VERA. This is calculated by dividing VERA's market cap by their current book value.
What is VERA's PB Ratio?
PB Ratio10.3x
BookUS$289.06m
Market CapUS$2.90b

Price to Book Ratio vs Peers

How does VERA's PB Ratio compare to its peers?

The above table shows the PB ratio for VERA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average464.3x
VSBC VitaSpring Biomedical
1847xn/aUS$3.1b
DYN Dyne Therapeutics
4.3x8.2%US$3.1b
AGIO Agios Pharmaceuticals
1.9x-56.7%US$3.1b
XENE Xenon Pharmaceuticals
3.8x12.7%US$3.0b
VERA Vera Therapeutics
10.3x17.0%US$2.9b

Price-To-Book vs Peers: VERA is expensive based on its Price-To-Book Ratio (10.3x) compared to the peer average (3.3x).

Price to Book Ratio vs Industry

How does VERA's PB Ratio compare vs other companies in the US Biotechs Industry?

61 CompaniesPrice / BookEstimated GrowthMarket Cap
GRAL GRAIL
0.2x35.7%US$507.04m
NKTX Nkarta
0.4x-11.5%US$176.42m
IMAB I-Mab
0.4x1.8%US$79.81m
ACET Adicet Bio
0.4x6.7%US$79.69m
VERA 10.3xIndustry Avg. 1.8xNo. of Companies84PB01.63.24.86.48+
61 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: VERA is expensive based on its Price-To-Book Ratio (10.3x) compared to the US Biotechs industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is VERA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VERA PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio10.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate VERA's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VERA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$47.03
US$64.58
+37.3%
30.5%US$107.00US$25.00n/a12
Nov ’25US$43.82
US$62.18
+41.9%
33.9%US$107.00US$25.00n/a11
Oct ’25US$42.83
US$57.70
+34.7%
37.5%US$107.00US$25.00n/a10
Sep ’25US$37.82
US$56.70
+49.9%
37.3%US$107.00US$25.00n/a10
Aug ’25US$37.62
US$57.20
+52.0%
36.7%US$107.00US$25.00n/a10
Jul ’25US$36.29
US$57.20
+57.6%
36.7%US$107.00US$25.00n/a10
Jun ’25US$37.99
US$57.20
+50.6%
36.7%US$107.00US$25.00n/a10
May ’25US$42.32
US$55.80
+31.9%
36.4%US$107.00US$25.00n/a10
Apr ’25US$42.35
US$47.78
+12.8%
24.0%US$60.00US$25.00n/a9
Mar ’25US$49.14
US$31.88
-35.1%
27.9%US$50.00US$21.00n/a8
Feb ’25US$38.00
US$32.11
-15.5%
26.2%US$50.00US$21.00n/a9
Jan ’25US$15.38
US$23.63
+53.6%
16.5%US$29.00US$16.00n/a8
Dec ’24US$13.84
US$22.86
+65.2%
15.6%US$27.00US$16.00n/a7
Nov ’24US$10.93
US$22.14
+102.6%
17.3%US$27.00US$16.00US$43.827
Oct ’24US$13.71
US$22.14
+61.5%
17.3%US$27.00US$16.00US$42.837
Sep ’24US$18.54
US$19.71
+6.3%
26.7%US$27.00US$10.00US$37.827
Aug ’24US$19.08
US$16.00
-16.1%
41.3%US$24.00US$7.00US$37.626
Jul ’24US$16.05
US$16.00
-0.3%
41.3%US$24.00US$7.00US$36.296
Jun ’24US$8.95
US$16.17
+80.6%
51.4%US$30.00US$7.00US$37.996
May ’24US$6.95
US$15.67
+125.4%
54.7%US$30.00US$6.00US$42.326
Apr ’24US$7.76
US$18.33
+136.3%
65.2%US$38.00US$6.00US$42.356
Mar ’24US$7.40
US$19.17
+159.0%
59.8%US$38.00US$6.00US$49.146
Feb ’24US$8.49
US$19.17
+125.8%
59.8%US$38.00US$6.00US$38.006
Jan ’24US$19.35
US$34.00
+75.7%
7.8%US$38.00US$30.00US$15.386
Dec ’23US$16.35
US$34.00
+108.0%
7.8%US$38.00US$30.00US$13.846
Nov ’23US$18.34
US$33.83
+84.5%
5.8%US$36.00US$30.00US$10.936

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Collegium Pharmaceutical

US$967.5m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.41

7D

0.5%

1Y

17.1%

IQVIA Holdings

US$35.3b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$197.60

7D

-2.6%

1Y

-5.7%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.86

7D

-5.2%

1Y

8.0%